New NNRTI Doravirine Is Non-Inferior to Darunavir/Ritonavir in Phase 3 Treatment-Naive Study
February 14, 2017
A late-breaker oral presented results from a phase 3 study comparing the NNRTI doravirine to boosted darunavir, showing similar viral suppression and low rates of side effects at the 48-week primary endpoint.1
Doravirine is a once-daily NNRTI from Merck that can be taken with or without food and few drug-interactions and that retains activity against common first generation NNRTI mutations (K103N, Y181C, G190A and E138K). Last year at CROI, results from a phase 2b study reported non-inferiority compared to efavirenz.2 A fixed dose combination of doravirine/TDF/3TC (using generic NRTIs) is already in phase 3 studies and a long-acting formulation is in development.3,4
The current study, presented by Jean-Micheal Molina from Hôpital St Louis in Paris, randomised 769 treatment-naive adults to either doravirine (100 mg) or darunavir/r (800 mg/ 100 mg), both once-daily with investigator choice of TDF/FTC (87%) or ABC/3TC (13%) as background nukes.
Baseline characteristics include mean age 35 years (SD+/- 10.5), 84% male, 73% white/ 22% black with 10% having a clinical history of advanced stage HIV. Mean CD4 and viral load were approximately 420 cells/mm3 (+/- 215) and 4.4 log copies/mL (+/- 0.7 log), with 20% >100,000 copies/mL and 4% >500,00 copies/mL.
At week 48, viral load was <50 copies/mL in 83.8% (321/383) vs 79.9% (306/383), in the doravirine vs darunavir/r arms respectively, (difference 3.9%, 95% CI [-1.6, 9.4]), showing non-inferiority. Results of the stratified analysis of participants with baseline viral load >100,000 copies/mL, were 81.0% (64/79) vs 76.4% (55/72) respectively. Similar suppression was reported for the 17 participants in the doravirine arms with baseline viral load >500,000 copies/mL.
CD4 increases were similar at week 48: 193 vs +186 cells/mm3 (difference +7; 95%CI -21 to +35.
Discontinuations were similar in each arm although slightly less with doravirine than darunavir/r (n=56 (15%) vs n=71 (19%), respectively). Reasons included loss to follow up (4% vs 5%), lack of efficacy 3% vs 4%), withdrawn consent (3% each arm), side effects (1% vs 3%), non-complianse (2% vs 1%), doctor decision (1% in each), pregnancy(n=1 vs 0), protocol violation (<1% vs 2%) and death (n=1 vs 0).
Drug-related side effects were similar between arms. Drug-related side effects were reported in just over 30% of each arm, serious side effects in 5% vs 6% and discontinuations by 1.6% vs 3.1% (doaravirine vs darunavir/r respectively)
The most common were diarrhoea (6% vs 13%), nausea (7% vs 8%), and headache (6% vs 3%) for doravirine vs darunavir/r respectively. Fasting LDL-C and non-HDL-C were reduced in the doravirine arm and increased in the darunavir/r arm (-4.5 and -5.3 vs +9.9 and +13.8 mg/dL, p<0.0001).
Drug resistance test in 7/19 vs 8/24 people who were non-responders or rebounders, included one person with both NRTI and INI resitance at week 24. This person was non adherent and discontinued at week 24. No PI mutations were observed.
Two posters will also be presented at CROI 2017 later this week: (i) on increased doravirine levels from a drug interaction with ritonavir5 and (ii) on the use in severe renal impairment (eGFR < 30 mL/min/1.73 m2).6
Summary results from these posters with be added to this report once the embargos are on Wednesday and Thursday afternoons respectively.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)